Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Sage Therapeutics, Inc.

Sage Therapeutics, Inc. (SAGE) Stock Overview

Explore Sage Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

SAGE●NASDAQ
HealthcareBiotechnology
$8.68
$0.00(0.00%)
U.S. Market is Open · 09:55

Sage Therapeutics, Inc. (SAGE)

Meyka AI Score

Z

Key Financials

Market Cap544.9M
P/E Ratio-4.82
EPS (TTM)$-4.89
ROE-0.29%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

SAGE Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Sage Therapeutics, Inc. (NASDAQ: SAGE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Sage Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of SAGE on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.

Key metrics behind Sage Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -4.82 and a market capitalization of 544.9M. Combined with our AI analysis, these give both institutional and retail investors a clear view of SAGE on the NASDAQ.

Price Performance (NASDAQ: SAGE)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
34.37%
6-Month Change
18.90%
Year-to-Date (YTD) Change
50.17%
1-Year Change
2.97%
3-Year Change
-77.24%
5-Year Change
-83.45%
All-Time (Max) Change
-71.16%

Contact Information

https://www.sagerx.com
617 299 8380
215 First Street, Cambridge, MA, 02142

Company Facts

3,530 Employees
IPO DateJul 18, 2014
CountryUS

Frequently Asked Questions